1-10 of 10
Andrew E. Aplin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4664.
https://doi.org/10.1158/1078-0432.CCR-21-2433
Published: 15 August 2021
View article titled, Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma
Open the PDF for Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma in another window
Journal Articles

Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3190–3200.
https://doi.org/10.1158/1078-0432.CCR-20-3363
Published: 01 June 2021
View article titled, Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma
Open the PDF for Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma in another window
Includes: Supplementary data
Journal Articles

The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)

Vivian Chua, Jane Mattei, Anna Han, Lauren Johnston, Kyleigh LiPira, Sara M. Selig, Richard D. Carvajal, Andrew E. Aplin, Sapna P. Patel
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (1): 28–33.
https://doi.org/10.1158/1078-0432.CCR-20-2536
Published: 04 January 2021
View article titled, The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)
Open the PDF for The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019) in another window
Journal Articles

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

Jessica L.F. Teh, Andrew E. Aplin
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 921–927.
https://doi.org/10.1158/1078-0432.CCR-18-1967
Published: 01 February 2019
View article titled, Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Open the PDF for Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment in another window
Journal Articles

Playing the Melanoma Endgame

Jessica L.F. Teh, Andrew E. Aplin
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4629–4630.
https://doi.org/10.1158/1078-0432.CCR-18-0989
Published: 01 October 2018
View article titled, Playing the Melanoma Endgame
Open the PDF for Playing the Melanoma Endgame in another window
Journal Articles

Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho

Reeti Behera, Amanpreet Kaur, Marie R. Webster, Suyeon Kim, Abibatou Ndoye, Curtis H. Kugel, III, Gretchen M. Alicea, Joshua Wang, Kanad Ghosh, Phil Cheng, Sofia Lisanti, Katie Marchbank, Vanessa Dang, Mitchell Levesque, Reinhard Dummer, Xiaowei Xu, Meenhard Herlyn, Andrew E. Aplin, Alexander Roesch, Cecilia Caino, Dario C. Altieri, Ashani T. Weeraratna
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3181–3190.
https://doi.org/10.1158/1078-0432.CCR-17-0201
Published: 14 June 2017
View article titled, Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
Open the PDF for Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho in another window
Includes: Supplementary data
Journal Articles

Abstract A31: 14-3-3 binding sites in full-length and splice variant forms of BRAF V600E modulate the response to RAF inhibitors

Michael J. Vido, Kaitlyn Le, Justin Rock, Edward J. Hartsough, Neda Dadpey, Andrew E. Aplin
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1_Supplement): A31.
https://doi.org/10.1158/1557-3265.PMCCAVULN16-A31
Published: 02 January 2017
View article titled, Abstract A31: 14-3-3 binding sites in full-length and splice variant forms of BRAF V600E modulate the response to RAF inhibitors
Journal Articles

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine

Edward J. Hartsough, Andrew E. Aplin
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1550–1552.
https://doi.org/10.1158/1078-0432.CCR-15-3054
Published: 31 March 2016
View article titled, Of Mice and Melanoma: PDX System for Modeling Personalized Medicine
Open the PDF for Of Mice and Melanoma: PDX System for Modeling Personalized Medicine in another window
Journal Articles

Abstract IA18: ERK activity in mutant BRAF melanoma – A live report

Andrew E. Aplin
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): IA18.
https://doi.org/10.1158/1557-3265.PMS14-IA18
Published: 13 February 2015
View article titled, Abstract IA18: ERK activity in mutant BRAF melanoma – A live report
Journal Articles

Abstract B8: FOXD3 enhances expression of ERBB3 and promotes resistance to vemurafenib

Kevin J. Basile, Ethan V. Abel, Andrew E. Aplin
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B8.
https://doi.org/10.1158/1078-0432.MECHRES-B8
Published: 04 March 2013
View article titled, Abstract B8: FOXD3 enhances expression of ERBB3 and promotes resistance to vemurafenib
Open the PDF for Abstract B8: FOXD3 enhances expression of ERBB3 and promotes resistance to vemurafenib in another window